Single administration of fosaprepitant meglumine was no less effective than 5-day administration of aprepitant for preventing acute and delayed nausea and vomiting symptoms occurring after administration of cisplatin-based chemotherapy regimens, a new study published online in the journal Supportive Care in Cancer has shown.
For the study, researchers sought to compare the impact of 5-day aprepitant with single administration of fosaprepitant meglumine, the intravenous formulation of aprepitant, on the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin-based chemotherapy.
Researchers enrolled 101 patients who received chemotherapy for esophageal, gastric, head and neck, or lung cancer with a regimen containing cisplatin 60 mg/m2 or higher. Participants were randomly assigned to receive either aprepitant for 5 days or one dose of fosaprepitant meglumine.
Results showed no significant differences in the complete response rate or the complete control rate over the 7-day period following the first cisplatin administration.
We aimed to compare the preventive effect of 5-day administration of aprepitant with single administration of fosaprepitant meglumine against nausea and vomiting symptoms due to highly emetogenic chemotherapy regimens comprising cisplatin (CDDP).